Drugs.com - New Drug Approvals

FDA Approves Jobevne (bevacizumab-nwgd), a Biosimilar to Avastin

BRIDGEWATER, New Jersey and BENGALURU, Karnataka, India, April 10, 2025 -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved...

Apr 15, 2025 - 03:42
 0
FDA Approves Jobevne (bevacizumab-nwgd), a Biosimilar to Avastin
BRIDGEWATER, New Jersey and BENGALURU, Karnataka, India, April 10, 2025 -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved...
Read More

Tags:

Previous Article

Research Team Leader (AE687038)

Next Article

First Quantum pays premium for Prospect copper exposure

Related Posts

FDA Grants Interchangeable Designation to Yuflyma (adalimumab-aaty), Celltrion's Biosimilar to Humira (adalimumab)

FDA Grants Interchangeable Designation to Yuflyma (adal...

Apr 15, 2025  0

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for...

Feb 9, 2025  0

FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications

FDA Approves Opdivo Qvantig (nivolumab and hyaluronidas...

Feb 9, 2025  0